This “ZULRESSO Drug Insight and Market Forecast - 2032” report provides comprehensive insights about ZULRESSO for postpartum depression (PPD) in the United States. A detailed picture of the ZULRESSO for PPD in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the ZULRESSO for PPD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZULRESSO market forecast analysis for PPD in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PPD.
Drug Summary
ZULRESSO (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA), a receptor-positive modulator indicated for treating PPD in adults. ZULRESSO was granted a Priority Review and was designated a breakthrough treatment by the FDA. ZULRESSO is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. The mechanism of action of brexanolone in the treatment of PPD in adults is related to its positive allosteric modulation of GABAA receptors. ZULRESSO potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing α1β2γ2 receptor subunits, α4β3δ receptor subunits, and α6β3δ receptor subunits. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults.
Scope of the Report
The report provides insights into:
- A comprehensive product overview including the ZULRESSO description, mechanism of action, dosage and administration, research and development activities in postpartum depression (PPD).
- Elaborated details on ZULRESSO regulatory milestones and other development activities have been provided in this report.
- The report also highlights the ZULRESSO research and development activities in PPD across the United States.
- The report also covers the patents information with expiry timeline around ZULRESSO.
- The report contains forecasted sales of ZULRESSO for PPD till 2032.
- Comprehensive coverage of the late-stage emerging therapies for PPD.
- The report also features the SWOT analysis with analyst views for ZULRESSO in PPD.
Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ZULRESSO Analytical Perspective
In-depth ZULRESSO Market Assessment
This report provides a detailed market assessment of ZULRESSO for postpartum depression (PPD) in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
ZULRESSO Clinical Assessment
The report provides the clinical trials information of ZULRESSO for PPD covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for postpartum depression (PPD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZULRESSO dominance.
- Other emerging products for PPD are expected to give tough market competition to ZULRESSO and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZULRESSO in PPD.
- This in-depth analysis of the forecasted sales data of ZULRESSO from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZULRESSO in PPD.
Key Questions
- What is the product type, route of administration and mechanism of action of ZULRESSO?
- What is the clinical trial status of the study related to ZULRESSO in postpartum depression (PPD) and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZULRESSO development?
- What are the key designations that have been granted to ZULRESSO for PPD?
- What is the forecasted market scenario of ZULRESSO for PPD?
- What are the forecasted sales of ZULRESSO in the United States?
- What are the other emerging products available and how are these giving competition to ZULRESSO for PPD?
- Which are the late-stage emerging therapies under development for the treatment of PPD?
This product will be delivered within 2 business days.
